Trial · NCT05770466
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.
NCT05770466, Phase 3, Completed, National Taiwan University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19. Trials, record NCT05770466. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05770466
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.
- NCT number
- NCT05770466
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 134 participants, actual
- Lead sponsor
- National Taiwan University Hospital
- Conditions
- COVID-19
- Interventions
- P1101 (Ropeginterferon alfa-2b), SOC
- First posted
- 2023-03-15
- Last updated
- 2024-04-16
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients who are negative to SARS-CoV-2 at Day 8 | Up to Day 8 | Proportion of patients who are negative to SARS-CoV-2 based on quantitative (Ct value ≥30) RT-PCR at Day 8 or discharge before Day 8 due to recovery |
| Primary | Time to discharge from hospital | Up to Day 29 | Time to discharge from hospital according to the latest Taiwan CDC guidance for SARS-CoV-2 infection (From randomization to discharge) |
| Secondary | Proportion of patients who are negative to SARS-CoV-2 at Day 5 | Up to Day 5 | Proportion of patients who are negative to SARS-CoV-2 based on quantitative (Ct value ≥30) RT-PCR at Day 5 or discharge before Day 5 due to recovery |
| Secondary | Change in clinical status of patient at Day 5 | Up to Day 5 | Change in clinical status of patient on WHO clinical progression scale at Day 5 |
| Secondary | Change in clinical status of patient at Day 8 | Up to Day 8 | Change in clinical status of patient on WHO clinical progression scale at Day 8 |
| Secondary | Change of SpO2 | Up to Day 29 | Change of SpO2 from baseline |
| Secondary | Time from symptom onset to resolution of clinical signs and symptoms | Up to Day 29 | Time from the onset of clinical symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell) to the resolution of clinical signs and symptoms. |
| Secondary | Time from symptom onset to RT-PCR negative result | Up to Day 29 | Time from the onset of clinical symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell) to the RT-PCR negative result (Ct value ≥30). |
| Secondary | Time from RT-PCR positive result to the resolution of clinical signs and symptoms | Up to Day 29 | Time from RT-PCR positive result (Ct value \< 30) to the resolution of clinical signs and symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell) |
| Secondary | Time from RT-PCR positive result to RT-PCR negative result | Up to Day 29 | Time from RT-PCR positive result (Ct value \< 30) to RT-PCR negative result (Ct value ≥30) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05770466
GET https://conductscience.org/api/trials/v1/NCT05770466/registered